{"id":8120,"date":"2023-08-04T10:46:19","date_gmt":"2023-08-04T10:46:19","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8120"},"modified":"2023-08-04T10:46:19","modified_gmt":"2023-08-04T10:46:19","slug":"icos-cd278-icosl-cd275-pathway","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/icos-cd278-icosl-cd275-pathway\/","title":{"rendered":"ICOS [CD278] \u2013 ICOSL [CD275] Pathway"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Inducible T cell co-stimulator (ICOS; CD278) is an activating receptor expressed on the surface of activated cytotoxic T cells, regulatory T cells (Tregs), NK cells and other types of T cells, having a distinct and opposing function than CTLA-4. The ligand ICOSL (B7-H2; CD275) is expressed on antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. ICOS\/ICOSL signalling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. Recently, it has been shown that ICOS expression could be a useful predictive biomarker of response to checkpoint inhibitor treatments (e.g through the CTLA-4 axis).<\/p>\n\n\n\n

LIT:<\/strong>\u00a0\u00a0ICOS Co-Stimulation: Friend or Foe? D.J. Wikenheiser & J.S. Stumhofer; Front. Immunol.\u00a07,<\/strong>\u00a0304 (2016) \u2022 Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy: F. Amatore, et al.; Expert Opin. Ther. Targets\u00a022,<\/strong>\u00a0343 (2018)<\/p>\n\n\n\n

ICOSL (B7-H2\/CD275) (human) ELISA Kit\u00a0–\u00a0Biomarker for Autoimmune Diseases & Cancers<\/strong><\/p>\n\n\n\n

The ICOSL (B7-H2\/CD275) (human) ELISA Kit (Prod. No. AG-45B-0017<\/a>) is a sandwich ELISA for specific quantitative determination of soluble human ICOSL [B7-H2\/CD275] in serum, plasma and cell culture supernatants. This ELISA Kit shows a very high specificity and sensitivity (55pg\/ml).<\/p>\n\n\n\n

Biologically Active\u00a0ICOS and ICOSL Proteins<\/strong><\/p>\n\n\n\n

See Biologically Active\u00a0ICOS and ICOSL Proteins\u00a0here<\/a><\/p>\n\n\n\n

VALIDATED\u00a0Antibodies for ICOS and ICOSL Research<\/strong><\/p>\n\n\n\n

See VALIDATED\u00a0Antibodies for ICOS and ICOSL Research here<\/a><\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on\u00a0adipogen.com\/icos-icosl-pathway\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

ICOS\/ICOSL signalling leads to the activation, proliferation and survival of cytotoxic T cells, as well as the survival of memory T cells. <\/p>\n","protected":false},"author":13,"featured_media":8130,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,7,684,685],"class_list":["post-8120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-cancer","tag-pathway","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8120"}],"version-history":[{"count":8,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8120\/revisions"}],"predecessor-version":[{"id":8131,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8120\/revisions\/8131"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8130"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}